Rxsight Inc
RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adju… Read more
Rxsight Inc (RXST) - Total Liabilities
Latest total liabilities as of September 2025: $32.56 Million USD
Based on the latest financial reports, Rxsight Inc (RXST) has total liabilities worth $32.56 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Rxsight Inc - Total Liabilities Trend (2019–2024)
This chart illustrates how Rxsight Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Rxsight Inc Competitors by Total Liabilities
The table below lists competitors of Rxsight Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Hangzhou Haoyue Personal Care Co Ltd
SHG:605009
|
China | CN¥1.84 Billion |
|
Compagnie Financière Tradition SA
PINK:CFNCF
|
USA | $1.24 Billion |
|
Cooper Energy Ltd
AU:COE
|
Australia | AU$805.54 Million |
|
Zhenhai PetroChem Engineering
SHG:603637
|
China | CN¥310.20 Million |
|
Byggmax Group AB
ST:BMAX
|
Sweden | Skr2.95 Billion |
|
Acco Brands Corporation
NYSE:ACCO
|
USA | $1.59 Billion |
|
Delixi Xinjiang Transp Co Ltd
SHG:603032
|
China | CN¥384.50 Million |
|
Chongqing Sulian Plastic Co. Ltd. A
SHE:301397
|
China | CN¥732.46 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Rxsight Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.74 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Rxsight Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Rxsight Inc (2019–2024)
The table below shows the annual total liabilities of Rxsight Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $37.33 Million | +68.22% |
| 2023-12-31 | $22.19 Million | -63.18% |
| 2022-12-31 | $60.26 Million | +10.62% |
| 2021-12-31 | $54.48 Million | -86.32% |
| 2020-12-31 | $398.21 Million | -4.06% |
| 2019-12-31 | $415.04 Million | -- |